Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-J591 Plus 177Lu-PSMA Small Molecule in Progressive mCRPC
NCT04886986Phase 1Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2021
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of CONV01-α in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoints: Dose Limiting Toxicity at 12 weeks, Maximum Tolerated Dose at 12 weeks and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
CONV01-α
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04886986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886986.